Literature DB >> 9792861

Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.

P N Tonin1, A M Mes-Masson, P A Futreal, K Morgan, M Mahon, W D Foulkes, D E Cole, D Provencher, P Ghadirian, S A Narod.   

Abstract

We have identified four mutations in each of the breast cancer-susceptibility genes, BRCA1 and BRCA2, in French Canadian breast cancer and breast/ovarian cancer families from Quebec. To identify founder effects, we examined independently ascertained French Canadian cancer families for the distribution of these eight mutations. Mutations were found in 41 of 97 families. Six of eight mutations were observed at least twice. The BRCA1 C4446T mutation was the most common mutation found, followed by the BRCA2 8765delAG mutation. Together, these mutations were found in 28 of 41 families identified to have a mutation. The odds of detection of any of the four BRCA1 mutations was 18.7x greater if one or more cases of ovarian cancer were also present in the family. The odds of detection of any of the four BRCA2 mutations was 5.3x greater if there were at least five cases of breast cancer in the family. Interestingly, the presence of a breast cancer case <36 years of age was strongly predictive of the presence of any of the eight mutations screened. Carriers of the same mutation, from different families, shared similar haplotypes, indicating that the mutant alleles were likely to be identical by descent for a mutation in the founder population. The identification of common BRCA1 and BRCA2 mutations will facilitate carrier detection in French Canadian breast cancer and breast/ovarian cancer families.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9792861      PMCID: PMC1377544          DOI: 10.1086/302099

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  52 in total

1.  [Demographic reproduction and genetic transmission in the north-east of the province of Quebec (18th-20th centuries)].

Authors:  G Bouchard; C Laberge; C R Scriver
Journal:  Eur J Popul       Date:  1988-09

2.  Founder effect in beta-thalassaemia in Portneuf, Québec.

Authors:  M De Braekeleer; T N Dao
Journal:  Nouv Rev Fr Hematol       Date:  1993-08

3.  BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing.

Authors:  D Shattuck-Eidens; A Oliphant; M McClure; C McBride; J Gupte; T Rubano; D Pruss; S V Tavtigian; D H Teng; N Adey; M Staebell; K Gumpper; R Lundstrom; M Hulick; M Kelly; J Holmen; B Lingenfelter; S Manley; F Fujimura; M Luce; B Ward; L Cannon-Albright; L Steele; K Offit; A Thomas
Journal:  JAMA       Date:  1997-10-15       Impact factor: 56.272

4.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

Authors:  Y Miki; J Swensen; D Shattuck-Eidens; P A Futreal; K Harshman; S Tavtigian; Q Liu; C Cochran; L M Bennett; W Ding
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

Review 5.  Familial hypercholesterolemia in French-Canadians: taking advantage of the presence of a "founder effect".

Authors:  J Davignon; M Roy
Journal:  Am J Cardiol       Date:  1993-09-30       Impact factor: 2.778

6.  Clinical, metabolic, and genetic aspects of cytochrome C oxidase deficiency in Saguenay-Lac-Saint-Jean.

Authors:  C Morin; G Mitchell; J Larochelle; M Lambert; H Ogier; B H Robinson; M De Braekeleer
Journal:  Am J Hum Genet       Date:  1993-08       Impact factor: 11.025

7.  Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families.

Authors:  J Simard; P Tonin; F Durocher; K Morgan; J Rommens; S Gingras; C Samson; J F Leblanc; C Bélanger; F Dion
Journal:  Nat Genet       Date:  1994-12       Impact factor: 38.330

8.  Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis.

Authors:  R Rozen; M De Braekeleer; J Daigneault; L Ferreira-Rajabi; M Gerdes; L Lamoureux; G Aubin; F Simard; T M Fujiwara; K Morgan
Journal:  Am J Med Genet       Date:  1992-02-01

9.  An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium.

Authors:  S A Narod; D Ford; P Devilee; R B Barkardottir; H T Lynch; S A Smith; B A Ponder; B L Weber; J E Garber; J M Birch
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

10.  A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening.

Authors:  D Shattuck-Eidens; M McClure; J Simard; F Labrie; S Narod; F Couch; K Hoskins; B Weber; L Castilla; M Erdos
Journal:  JAMA       Date:  1995-02-15       Impact factor: 56.272

View more
  56 in total

Review 1.  Forth nightly review: hereditary ovarian carcinoma.

Authors:  L Kasprzak; W D Foulkes; A N Shelling
Journal:  BMJ       Date:  1999-03-20

2.  Characterization of four novel epithelial ovarian cancer cell lines.

Authors:  D M Provencher; H Lounis; L Champoux; M Tétrault; E N Manderson; J C Wang; P Eydoux; R Savoie; P N Tonin; A M Mes-Masson
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-06       Impact factor: 2.416

Review 3.  Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms.

Authors:  H Wu; X Wu; Z Liang
Journal:  Gene Ther       Date:  2017-08-03       Impact factor: 5.250

4.  Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families.

Authors:  Hélène Vézina; Francine Durocher; Martine Dumont; Louis Houde; Csilla Szabo; Martine Tranchant; Jocelyne Chiquette; Marie Plante; Rachel Laframboise; Jean Lépine; Heli Nevanlinna; Dominique Stoppa-Lyonnet; David Goldgar; Peter Bridge; Jacques Simard
Journal:  Hum Genet       Date:  2005-05-10       Impact factor: 4.132

Review 5.  Mutations in context: implications of BRCA testing in diverse populations.

Authors:  Gabriela E S Felix; Yonglan Zheng; Olufunmilayo I Olopade
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

6.  Evidence for an ancient BRCA1 mutation in breast cancer patients of Yoruban ancestry.

Authors:  Bifeng Zhang; James D Fackenthal; Qun Niu; Dezheng Huo; Walmy E Sveen; Tiffani DeMarco; Clement A Adebamowo; Temidayo Ogundiran; Olufunmilayo I Olopade
Journal:  Fam Cancer       Date:  2008-08-05       Impact factor: 2.375

7.  Familial prostate cancer: the damage done and lessons learnt.

Authors:  Nassim Taherian; Nancy Hamel; Louis R Bégin; Tarek A Bismar; David E Goldgar; Bing-Jian Feng; William D Foulkes
Journal:  Nat Rev Urol       Date:  2013-01-15       Impact factor: 14.432

8.  Double primary cancers of the breast and thyroid in women: molecular analysis and genetic implications.

Authors:  T Pal; N Hamel; D Vesprini; K Sanders; M Mitchell; N Quercia; N Ng Cheong; A Murray; W Foulkes; S A Narod
Journal:  Fam Cancer       Date:  2001       Impact factor: 2.375

9.  A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian population.

Authors:  Grazia Palomba; Angela Loi; Antonella Uras; Patrizia Fancello; Giovanna Piras; Attilio Gabbas; Antonio Cossu; Mario Budroni; Antonio Contu; Francesco Tanda; Antonio Farris; Sandra Orrù; Carlo Floris; Marina Pisano; Mario Lovicu; Maria Cristina Santona; Gennaro Landriscina; Laura Crisponi; Giuseppe Palmieri; Maria Monne
Journal:  BMC Cancer       Date:  2009-07-20       Impact factor: 4.430

10.  The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.

Authors:  S R Young; Robert T Pilarski; Talia Donenberg; Charles Shapiro; Lyn S Hammond; Judith Miller; Karen A Brooks; Stephanie Cohen; Beverly Tenenholz; Damini Desai; Inuk Zandvakili; Robert Royer; Song Li; Steven A Narod
Journal:  BMC Cancer       Date:  2009-03-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.